Exploration of Targeted Anti-tumor Therapy,
Journal Year:
2024,
Volume and Issue:
5(6), P. 1223 - 1246
Published: Sept. 29, 2024
Oral
squamous
cell
carcinoma
(OSCC)
is
a
highly
malignant
and
invasive
tumor
with
significant
mortality
morbidity.
Current
treatment
modalities
such
as
surgery,
radiotherapy,
chemotherapy
encounter
limitations,
poor
targeting,
systemic
toxicity,
drug
resistance.
There
an
urgent
need
for
novel
therapeutic
strategies
that
offer
targeted
delivery,
enhanced
efficacy,
reduced
side
effects.
The
advent
of
lipid-based
nanoparticles
(LNPs)
offers
promising
tool
OSCC
therapy,
potentially
overcoming
the
limitations
current
approaches.
LNPs
are
composed
biodegradable
biocompatible
lipids,
which
minimize
risk
toxicity
adverse
can
encapsulate
hydrophobic
drugs,
improving
their
solubility
stability
in
biological
environment,
thereby
enhancing
bioavailability.
demonstrate
significantly
higher
ability
to
lipophilic
drugs
than
other
nanoparticle
types.
excellent
storage
stability,
minimal
leakage,
controlled
release,
making
them
effective
nanoplatforms
delivery
chemotherapeutic
agents.
Additionally,
be
modified
by
complexing
specific
target
ligands
on
surface.
This
surface
modification
allows
active
targeting
tumors
addition
passive
mechanism.
Furthermore,
PEGylation
improves
hydrophilicity
enhances
half-life
reducing
clearance
reticuloendothelial
system.
review
aims
discuss
approaches
well
recent
advancements
better
management
OSCC.
Molecular Pharmaceutics,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 4, 2025
Antiangiogenic
medications
for
cancer
treatment
have
generally
failed
in
showing
substantial
benefits
terms
of
prolonging
life
on
their
own;
effects
are
noticeable
only
when
combined
with
chemotherapy.
Moreover,
treatments
based
prolonged
antiangiogenics
administration
demonstrated
to
be
ineffective
stopping
tumor
progression.
In
this
scenario,
nanotherapeutics
can
address
certain
issues
linked
existing
antiangiogenic
treatments.
More
specifically,
they
provide
the
ability
target
tumor's
blood
vessels
enhance
drug
accumulation
and
manage
release,
ultimately
decreasing
undesired
side
effects.
Additionally,
enable
multiple
angiogenesis
inhibitors
at
same
time
as
Key
reports
field
include
design
polymeric
nanoparticles,
inorganic
vesicles,
hydrogels
loading
substances
like
endostatin
interleukin-12.
Furthermore,
nanoformulations
been
proposed
efficiently
control
relevant
pro-angiogenic
pathways
such
VEGF,
Tie2/Angiopoietin-1,
HIF-1α/HIF-2α,
TGF-β,
providing
powerful
approaches
block
growth
metastasis.
article,
we
outline
a
selection
that
developed
past
ten
years.
Exploration of Targeted Anti-tumor Therapy,
Journal Year:
2024,
Volume and Issue:
5(6), P. 1223 - 1246
Published: Sept. 29, 2024
Oral
squamous
cell
carcinoma
(OSCC)
is
a
highly
malignant
and
invasive
tumor
with
significant
mortality
morbidity.
Current
treatment
modalities
such
as
surgery,
radiotherapy,
chemotherapy
encounter
limitations,
poor
targeting,
systemic
toxicity,
drug
resistance.
There
an
urgent
need
for
novel
therapeutic
strategies
that
offer
targeted
delivery,
enhanced
efficacy,
reduced
side
effects.
The
advent
of
lipid-based
nanoparticles
(LNPs)
offers
promising
tool
OSCC
therapy,
potentially
overcoming
the
limitations
current
approaches.
LNPs
are
composed
biodegradable
biocompatible
lipids,
which
minimize
risk
toxicity
adverse
can
encapsulate
hydrophobic
drugs,
improving
their
solubility
stability
in
biological
environment,
thereby
enhancing
bioavailability.
demonstrate
significantly
higher
ability
to
lipophilic
drugs
than
other
nanoparticle
types.
excellent
storage
stability,
minimal
leakage,
controlled
release,
making
them
effective
nanoplatforms
delivery
chemotherapeutic
agents.
Additionally,
be
modified
by
complexing
specific
target
ligands
on
surface.
This
surface
modification
allows
active
targeting
tumors
addition
passive
mechanism.
Furthermore,
PEGylation
improves
hydrophilicity
enhances
half-life
reducing
clearance
reticuloendothelial
system.
review
aims
discuss
approaches
well
recent
advancements
better
management
OSCC.
